Size dependence of the magnetic relaxation and specific power absorption in iron oxide nanoparticles
- 779 Downloads
In this study, magnetic and power absorption properties of a series of iron oxide nanoparticles with average sizes 〈d〉 ranging from 3 to 23 nm were reported. The nanoparticles were prepared by thermal decomposition of Iron(III) acetylacetonate in organic media. From the careful characterization of the magnetic and physicochemical properties of these samples, the specific power absorption (SPA) values experimentally found were numerically reproduced, as well as their dependence with particle size, using a simple model of Brownian and Néel relaxation at room temperature. SPA experiments in ac magnetic fields (H0 = 13 kA/m and f = 250 kHz) indicated that the magnetic and rheological properties played a crucial role determining the heating efficiency at different conditions. A maximum SPA value of 344 W/g was obtained for a sample containing nanoparticles with 〈d〉 = 12 nm and dispersion σ = 0.25. The observed SPA dependence with particle diameter and their magnetic parameters indicated that, for the size range and experimental conditions of f and H studied in this study, both Néel and Brown relaxation mechanisms are important to the heat generation observed.
KeywordsMagnetic nanoparticles Magnetic losses Superparamagnetism Electromagnetic heating
This study was supported partially from Diputación General de Aragon (DGA) and Ministerio de Economia y Competitividad (MINECO, Project MAT2010-19326), Spain. Partial support from the Brazilian agency FAPESP is also acknowledged. E. Lima Jr. acknowledges financial support from the FAPESP through a postdoctoral fellowship.
Conflict of interest
The authors declare that they do not have any affiliations that would lead to a conflict of interest.
- Maier-Hauff K, lrich F, Nestler D, Niehoff H, Wust P, Thiesen B, Orawa H, Budach V, Jordan A (2011) Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol 103(2):317–324CrossRefGoogle Scholar